DIALOGUE 1 was a placebo-controlled study in NDD-CKD, DIALOGUE 2 was an open-label study where DA was switched to molidustat in NDD-CKD, and DIALOGUE 4 was an open-label study where epoetin α was switched to molidustat in DD-CKD. The gene discussed is EPO; the disease is chronic kidney disease.